This Phase 1/2 study evaluated safety and efficacy of a topical anhydrous ointment, SOR007, which contains submicron particles of the chemotherapy Taxol primarily in breast cancer patients with cutaneous metastases.
One of three concentrations of SOR007 (0.15%, 1.0%, or 2.0%) was applied twice daily over an area of 50 cm2 for up to 28 days, with the option for expansion to an additional 28 days at the highest dose under a Phase 2a study once safety was established.
Efficacy was analyzed by lesion measurements and photographs to determine Response Rate (reduction in size by at least 30%), Complete Response (100% reduction, disappearance), and Progression Free Survival (time until the metastases came back) by day 28 or 56.
Results in Cutaneous Metastases of Breast Cancer
23 patients were enrolled, 21 with cutaneous metastases of breast cancer. 4 patients received SOR007 0.15% for a median of 28 days, 3 at a dose of 1.0% for a median of 28 days, and 16 at 2.0% for a median of 55 days.
All doses were well tolerated, and 19 patients were evaluable for efficacy.
The proportion of patients being without progression at 28 days across all treatments was 79%.
Lesion stabilization was observed in most subjects over the study period.
Key Messages for Breast Cancer Patients
The findings showed that topical SOR007 was well-tolerated, with pain reduction in 64% of the patients.
Topical SOR007 led to cutaneous metastases lesion stabilization or improvement in the majority of the patients over a 1- to 2-month period.
Systemic Taxol absorption was negligible.
Talk to us so see if we can help you to actually get the most advanced treatments
Because we, do not give up on life!
Contact us 24/7 –
Call center +44.2082.426.039